12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

U.S. Food and Drug Administration regulatory update

FDA will hold a public workshop on April 25-26 to discuss therapies to treat myalgic encephalomyelitis and chronic fatigue syndrome (CFS). The workshop will gather patient perspectives and identify quantitative outcome measures to determine if disease symptoms improve with specific drug treatments. The workshop is part of...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >